Bright Uro Inc.
Bright Uro is dedicated to revolutionizing urodynamics by developing innovative, comfortable, and precise tools to improve diagnosis and monitoring of lower urinary tract conditions. Their mission is to transform care for lower urinary tract dysfunction through groundbreaking urodynamics solutions, including the wireless, catheter-free Glean Urodynamics System, which aims to enhance patient comfort, streamline clinical workflows, and provide high-quality real-world data for better diagnostic accuracy and treatment planning.
Industries
Nr. of Employees
small (1-50)
Bright Uro Inc.
Patents
Packaging assembly and method of preparing sensing device for insertion into a body cavity to preserve sterility
US-12426818-B2
View Details
Packaging assembly and method of preparing sensing device for insertion into a body cavity to preserve sterility
US-12426818-B2
View DetailsProducts
Catheter-free ambulatory urodynamics platform
Integrated ambulatory urodynamics system composed of an insertable wireless intravesical pressure sensor, insertion tooling, a uroflowmeter, clinician and patient mobile applications, and web/admin portals for data review and management.
Catheter-free ambulatory urodynamics platform
Integrated ambulatory urodynamics system composed of an insertable wireless intravesical pressure sensor, insertion tooling, a uroflowmeter, clinician and patient mobile applications, and web/admin portals for data review and management.
Services
Online short-format course covering system components, sensor and uroflowmeter preparation, deployment procedures, monitoring, removal, and data download/analysis for clinicians and clinical staff.
On-site or remote demonstrations and initial deployments to evaluate system fit in clinic workflows and support early clinical adoption of ambulatory urodynamic testing.
Online short-format course covering system components, sensor and uroflowmeter preparation, deployment procedures, monitoring, removal, and data download/analysis for clinicians and clinical staff.
On-site or remote demonstrations and initial deployments to evaluate system fit in clinic workflows and support early clinical adoption of ambulatory urodynamic testing.
Expertise Areas
- Ambulatory urodynamic monitoring
- Clinical study design and first-in-human validation
- Digital health software for clinicians and patients
- Signal processing and real-time physiological event classification
Key Technologies
- Telemetric intravesical pressure sensing
- Uroflowmetry (flow and volume sensors)
- Low-power wireless telemetry for physiological sensors
- Mobile clinical and patient applications
News & Updates
Bright Uro announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean™ Urodynamics System, a wireless, catheter-free ambulatory urodynamics device designed to support clinical decision making for patients with lower urinary tract dysfunction (LUTD) and other urologic conditions.
Bright Uro has earned FDA 510(k) clearance for its Glean urodynamics system, which overcomes current catheter-based urethral pressure testing limitations, providing a more comfortable and precise diagnostic method.
Bright Uro raised $23 million in Series A funds to support FDA clearance and U.S. product launch of the Glean urodynamics system, which offers wireless, catheter-free assessment of bladder and urethra function.
Bright Uro launched with $6 million in seed financing and a grant from the NIH to develop its wireless, catheter-free Glean Urodynamics System, licensed from Cleveland Clinic.
Bright Uro has appointed Martha Goldberg Aronson and Dr. Sanford Siegel to its Board of Directors and Advisors to provide leadership and guidance for upcoming product launches.
A recent study published in the Journal of Endourology demonstrated that the Glean™ Urodynamics System is safe, well-tolerated, and enables ambulatory urodynamics without catheters impeding lower urinary tract function.
Bright Uro announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Glean™ Urodynamics System, a wireless, catheter-free ambulatory urodynamics device designed to support clinical decision making for patients with lower urinary tract dysfunction (LUTD) and other urologic conditions.
Bright Uro has earned FDA 510(k) clearance for its Glean urodynamics system, which overcomes current catheter-based urethral pressure testing limitations, providing a more comfortable and precise diagnostic method.
Bright Uro raised $23 million in Series A funds to support FDA clearance and U.S. product launch of the Glean urodynamics system, which offers wireless, catheter-free assessment of bladder and urethra function.
Bright Uro launched with $6 million in seed financing and a grant from the NIH to develop its wireless, catheter-free Glean Urodynamics System, licensed from Cleveland Clinic.
Bright Uro has appointed Martha Goldberg Aronson and Dr. Sanford Siegel to its Board of Directors and Advisors to provide leadership and guidance for upcoming product launches.
A recent study published in the Journal of Endourology demonstrated that the Glean™ Urodynamics System is safe, well-tolerated, and enables ambulatory urodynamics without catheters impeding lower urinary tract function.